Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis  Emily Edson-Heredia, Kimberly L. Sterling, Carlos I. Alatorre, Gebra Cuyun Carter, Rosirene Paczkowski, Victoria Zarotsky, Tomoko Maeda-Chubachi  Journal of Investigative Dermatology  Volume 134, Issue 1, Pages 18-23 (January 2014) DOI: 10.1038/jid.2013.326 Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Studies evaluating factors affecting treatment response and outcomes in patients with psoriasis. Levels of evidence presented are according to National Institute for Health and Clinical Excellence levels of evidence for published data (http://www.nice.org.uk/media/FA2/C8/GuidelinesManualChapters06.pdf, accessed 2 August 2012). Level 1—evidence based on meta-analyses, systematic reviews of randomized clinical trials, randomized controlled trials; level 2—evidence based on case-control or cohort studies (non-randomized controlled studies), systematic reviews of case-control studies; level 3—evidence based on non-analytic studies (case reports or series). Journal of Investigative Dermatology 2014 134, 18-23DOI: (10.1038/jid.2013.326) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Studies evaluating potential factors associated with response to biologic agents in patients with psoriasis. *Results varied within the study depending on the analysis performed, time of assessment, or measure used to assess the factor of interest. **Two additional studies reported an effect on treatment response but provided no statistical data to support this finding. ***Previous treatment could be conventional agents or biologics; in several instances the study reports did not specify the type of previous therapy. BMI, body mass index; CRP, C-reactive protein. Journal of Investigative Dermatology 2014 134, 18-23DOI: (10.1038/jid.2013.326) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions